Randomized Phase II Study of Docetaxel plus Bevacizumab or Pemetrexed plus Bevacizumab for Elderly Non-Squamous NSCLC (TORG1323)

被引：0

作者：

Kozuki, Toshiyuki ^{[1
]}

Nogami, Naoyuki ^{[1
]}

Yamashita, Natsumi ^{[2
]}

Shinkai, Tetsu ^{[3
]}

Shukuya, Takehito ^{[4
,5
]}

Seki, Nobuhiko ^{[6
]}

Kato, Terufumi ^{[7
]}

Satouchi, Miyako ^{[8
]}

Masuda, Noriyuki ^{[9
]}

Watanabe, Koshiro ^{[10
]}

机构：

[1] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan

[2] Natl Hosp Org, Shikoku Canc Ctr, Clin Res Ctr, Matsuyama, Ehime, Japan

[3] Shonan East Gen Hosp, Dept Internal Med, Chigasaki, Kanagawa, Japan

[4] Juntendo Univ, Fac Med, Div Resp Med, Tokyo, Japan

[5] Grad Sch Med, Tokyo, Japan

[6] Teikyo Univ, Sch Med, Dept Med Oncol, Tokyo 173, Japan

[7] Kanagawa Cardiovasc & Resp Ctr, Resp Med, Yokohama, Kanagawa, Japan

[8] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan

[9] Kitasato Univ, Sch Med, Dept Resp Med, Kanagawa, Japan

[10] Thorac Oncol Res Grp, Yokohama, Kanagawa, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

elderly; Clinical Trial in Progress; NSCLC; bevacizumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.01-085

引用

页码：S666 / S666

页数：1

共 50 条

[21] The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC)
Ding, Lingyu
Liu, Kejun
Jiang, Zhelong
Chen, Qi
Zhou, Ningning
Liang, Ying
Gao, Hongfei
Hong, Xiangchan
Wu, Haiying
TUMOR BIOLOGY, 2015, 36 (04) : 2491 - 2499
[22] Pemetrexed plus Platinum Chemotherapy with or Without Immuno Responses of Bevacizumab plus Cisplatin for the Non-Squamous Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusions Therapy in Non-Squamous NSCLC: Descriptive Safety Analysis
Li, X.
Li, J.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2084 - S2084
[23] A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016)
Satoru Miura
Makoto Maemondo
Akira Iwashima
Toshiyuki Harada
Shunichi Sugawara
Kunihiko Kobayashi
Akira Inoue
Taku Nakagawa
Yuichi Takiguchi
Hiroshi Watanabe
Takashi Ishida
Masaki Terada
Hiroshi Kagamu
Akihiko Gemma
Hirohisa Yoshizawa
Investigational New Drugs, 2017, 35 : 227 - 234
[24] A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016)
Miura, Satoru
Maemondo, Makoto
Iwashima, Akira
Harada, Toshiyuki
Sugawara, Shunichi
Kobayashi, Kunihiko
Inoue, Akira
Nakagawa, Taku
Takiguchi, Yuichi
Watanabe, Hiroshi
Ishida, Takashi
Terada, Masaki
Kagamu, Hiroshi
Gemma, Akihiko
Yoshizawa, Hirohisa
INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 227 - 234
[25] Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG) 1016
Ikeda, Satoshi
Kato, Terufumi
Ogura, Takashi
Sekine, Akimasa
Oda, Tsuneyuki
Masuda, Noriyuki
Igawa, Satoshi
Katono, Ken
Otani, Sakiko
Yamada, Kouzo
Saito, Haruhiro
Kondo, Tetsuro
Hosomi, Yukio
Nakahara, Yoshiro
Nishikawa, Masanori
Utumi, Keiko
Misumi, Yuki
Yamanaka, Takeharu
Sakamaki, Kentaro
Okamoto, Hiroaki
BMC CANCER, 2018, 18
[26] Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
Satoshi Ikeda
Terufumi Kato
Takashi Ogura
Akimasa Sekine
Tsuneyuki Oda
Noriyuki Masuda
Satoshi Igawa
Ken Katono
Sakiko Otani
Kouzo Yamada
Haruhiro Saito
Tetsuro Kondo
Yukio Hosomi
Yoshiro Nakahara
Masanori Nishikawa
Keiko Utumi
Yuki Misumi
Takeharu Yamanaka
Kentaro Sakamaki
Hiroaki Okamoto
BMC Cancer, 18
[27] Bevacizumab plus Docetaxel and Cisplatin for Metastatic Breast Cancer: A Pilot Phase II Study
Tai, Cheng-Jeng
Chen, Ching-Shyang
Hung, Chin-Sheng
Kuo, Li-Jen
Wei, Po-Li
Chiou, Jeng-Feng
Hsu, Chung-Huei
Chiou, Hung-Yi
Wu, Chih-Hsiung
ANTICANCER RESEARCH, 2012, 32 (12) : 5501 - 5506
[28] PERLA: Randomized Phase II Trial of Dostarlimab plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic Non-Squamous NSCLC
Spira, A.
Lim, S. M.
Griesinger, F.
De Marinis, F.
Mccarthy, T.
Huseinovic, N.
O'Donnell, S.
Ahn, J. S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1013 - S1014
[29] PHASE II STUDY OF PEMETREXED plus CARBOPLATIN plus BEVACIZUMAB AS FIRST LINE THERAPY FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 0910 TRIAL
Kimura, Tomoki
Taniguchi, Hiroyuki
Ogasawara, Tomohiko
Suzuki, Ryujiro
Kondo, Masashi
Shindoh, Joe
Yoshida, Norio
Kojima, Eiji
Yamada, Yoshiyuki
Hataji, Osamu
Ichikawa, Motoshi
Saito, Hiroshi
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1167 - S1167
[30] Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer
Kaira, Kyoichi
Tomizawa, Yoshio
Yoshino, Reiko
Miura, Yosuke
Yoshii, Akihiro
Iwasaki, Yasuki
Koga, Yasuhiko
Ono, Akihiro
Hisada, Takeshi
Minato, Koichi
Sato, Koji
Kazama, Toshifumi
Ishihara, Shinichi
Kohyama, Kenya
Fueki, Naoto
Saito, Ryusei
Sunaga, Noriaki
LUNG CANCER, 2013, 82 (01) : 103 - 108

← 1 2 3 4 5 →